Home Cart Sign in  
Chemical Structure| 725247-18-7 Chemical Structure| 725247-18-7

Structure of XCT790
CAS No.: 725247-18-7

Chemical Structure| 725247-18-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

XCT-790 is an agonist of estrogen related receptor alpha (ERRα) and can induce death of cancer cells resistant to chemotherapy.

Synonyms: Compound 12

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of XCT790

CAS No. :725247-18-7
Formula : C23H13F9N4O3S
M.W : 596.43
SMILES Code : O=C(NC1=NN=C(C(F)(F)F)S1)/C(C#N)=C/C2=CC=C(OCC3=CC=C(C(F)(F)F)C=C3C(F)(F)F)C(OC)=C2
Synonyms :
Compound 12
MDL No. :MFCD08277031
InChI Key :HQFNFOOGGLSBBT-AWNIVKPZSA-N
Pubchem ID :6918788

Safety of XCT790

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H413
Precautionary Statements:P264-P270-P273-P301+P312-P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 5 μM 12 h XCT790 inhibited NDV-GFP expression, showing antiviral activity. PLoS Pathog. 2017 Jun 7;13(6):e1006347.
HeLa cells 5 μM 12 h XCT790 inhibited VSV-G protein expression, showing antiviral activity. PLoS Pathog. 2017 Jun 7;13(6):e1006347.
human valvular interstitial cells (hVICs) 6 µg/mL 8 h To evaluate the inhibitory effect of XCT790 on osteogenic differentiation of hVICs, results showed that XCT790 significantly reduced the expression of ALP and RUNX2, and inhibited calcium deposition. Nat Commun. 2024 Jan 16;15(1):557.
human valvular interstitial cells (hVICs) 20 µg/mL 8 h To evaluate the inhibitory effect of XCT790 on osteogenic differentiation of hVICs, results showed that XCT790 significantly reduced the expression of ALP and RUNX2, and inhibited calcium deposition. Nat Commun. 2024 Jan 16;15(1):557.
HCT-116 cells 2.5, 5, 10 μM 30 h XCT790 treatment resulted in ERRα degradation and inhibited migration of HCT-116 cells. Cancer Res. 2010 Nov 15;70(22):9298-308.
PC-3 cells 2.5, 5, 10 μM 30 h XCT790 treatment resulted in ERRα degradation and inhibited migration of PC-3 cells. Cancer Res. 2010 Nov 15;70(22):9298-308.
MDA-MB 436 cells 2.5, 5, 10 μM 30 h XCT790 treatment resulted in ERRα degradation and inhibited migration of MDA-MB 436 cells. Cancer Res. 2010 Nov 15;70(22):9298-308.
MDA-MB 231 cells 2.5, 5, 10 μM 30 h XCT790 treatment resulted in ERRα degradation and inhibited migration of MDA-MB 231 cells. Cancer Res. 2010 Nov 15;70(22):9298-308.
Endometrial cancer cells 12.5 µM 48 h XCT790 inhibits ERRα expression, reduces the proliferation of endometrial cancer cells, and enhances the therapeutic effect of carboplatin. Cell Death Dis. 2025 Mar 17;16(1):182.
293T cells 2.5 μM 12 h XCT790 significantly upregulated VSV-induced IFN-β and IFN-regulated gene expression and inhibited VSV production. PLoS Pathog. 2017 Jun 7;13(6):e1006347.
HCT116 cells 1.5 µM 24 h Induced EGFR expression, mimicking the effect of AM251 Br J Pharmacol. 2011 Oct;164(3):1026-40.
PANC-1 cells 1.5 µM 24 h Induced HB-EGF and EGFR expression, mimicking the effect of AM251 Br J Pharmacol. 2011 Oct;164(3):1026-40.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice High-fat diet-induced aortic valve calcification model Intravenous injection 600 µg/mouse Once per week for 8 weeks To evaluate the therapeutic effect of SR@PFeXCT on aortic valve calcification, results showed that SR@PFeXCT significantly alleviated aortic valve calcification and stenosis. Nat Commun. 2024 Jan 16;15(1):557.
BALB/c nude mice PC-9/GR xenograft model Intraperitoneal injection 8 mg/kg Daily for 21 days XCT790 synergized with gefitinib to significantly inhibit the growth of PC-9/GR xenograft tumors Mol Cancer. 2022 Mar 18;21(1):77
SCID mice VCaP-CRPC xenograft model Intraperitoneal injection 10 mg/kg Once daily for 3 weeks XCT790 treatment significantly inhibited tumor growth in the VCaP-CRPC xenograft model Theranostics. 2020 Mar 4;10(9):4201-4216

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.68mL

0.34mL

0.17mL

8.38mL

1.68mL

0.84mL

16.77mL

3.35mL

1.68mL

References

 

Historical Records

Categories